The market is becoming more and more polarized. On the one hand, some European startups have been struggling to refinance their growth for several years. On the other hand, a few companies manage to concentrate capital, investor attention and speed of execution at a pace rarely observed in European tech. Lucis is now part of this second category.
Founded in 2025 by Maxime Berthelot and Baptiste Debever, the French company specializing in preventive health has just raised $20 million in Series A from Singular, with the participation of General Catalyst, Y Combinator and several business angels from the European tech and healthtech ecosystem. This funding round comes just four months after an $8 million seed and brings the company’s total funding to $28 million.
Beyond the amount, it is above all the speed of execution that intrigues European investors. In less than a year, Lucis claims to have exceeded 10,000 users spread between France, the United Kingdom, Ireland and Portugal, while carrying out more than a million biomarker tests via partnerships with Eurofins and Randox.
The trajectory is reminiscent of the new acceleration patterns observed in certain AI startups with a very readable positioning, a technological promise immediately understandable by international funds and an ability to quickly transform usage into a market signal.
Lucis is positioning itself on health prevention assisted by artificial intelligence. The platform analyzes more than 110 blood biomarkers linked to metabolism, hormones, inflammation, cardiovascular risks or nutritional deficiencies. The data is then aggregated into an app capable of producing personalized recommendations for diet, supplements, sleep, lifestyle or follow-up tests.
The ambition displayed goes far beyond the simple enriched blood test, and Lucis seeks to build a continuous software layer around individual health, namely transforming prevention into a recurring digital product.
The speech has particularly attracted investors for several months. In a context of progressive saturation of European health systems and the explosion of chronic diseases, prevention is once again becoming a major economic subject. Platforms capable of producing large-scale longitudinal data are beginning to be seen as future strategic infrastructures.
This is precisely what Singular emphasizes when it talks about a “compounding data advantage”. The formula summarizes a logic that is now central to the AI economy: the more a platform accumulates consistent data over time, the more it improves its predictive capabilities, its user engagement and its barriers to entry.
In the case of Lucis, this data loop relies on repeating biological analyses. More than 80% of users would have chosen to carry out a new test after their first analysis, a particularly high rate for a still recent platform. Among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication.
These figures obviously contribute to the story of society’s growth, but they also reflect a more profound transformation of the relationship with health. For decades, Western medical systems have been built around intervention after symptoms appear. On the contrary, new prevention platforms seek to install continuous monitoring logic, powered by biological data and conversational interfaces.
The phenomenon now goes beyond the scope of quantified self or consumer wearables. After connected watches and sleep monitoring, part of healthtech is now trying to transform biological analyzes into permanent digital infrastructure.
This development is gradually bringing certain health startups closer to traditional SaaS models. The value no longer lies solely in the test itself, but in the ability to maintain recurring engagement, enrich predictive models and build an ongoing relationship with the user.
This is probably what explains the interest of investors like General Catalyst, very active in AI infrastructures applied to health. For several years, the American fund has defended a vision according to which future medical platforms will be built around software layers capable of orchestrating clinical data, biomarkers, generative AI and longitudinal patient monitoring.
However, a central question remains: where is the border between medical prevention, personal optimization and augmented medicine? Because behind the promise of democratization of prevention also looms the risk of healthcare driven by subscription, where access to permanent biological monitoring would gradually become an advantage reserved for the most solvent populations.
The regulatory issue could also become critical as these platforms gain sophistication. The more AI systems produce prescriptive recommendations (nutrition, supplementation, clinical interpretation or early detection of risks) the more European authorities will be forced to regulate the associated medical responsibilities.
For the moment, the market remains largely open in Europe, unlike in the United States, where several players are already competing in the personalized prevention segment, the European ecosystem remains fragmented. It is precisely this window that Lucis is trying to exploit with an announced expansion to Spain, Germany and Italy by the end of 2026.
Above all, the company’s journey illustrates a new reality in the European ecosystem: financing cycles are accelerating, rounds are growing faster and investors are now seeking to identify very early on platforms capable of locking in strategic data flows.
